Asthma COPD overlap syndrome
AsthmaโCOPD Overlap Syndrome (ACOS) refers to patients exhibiting features of both asthma and COPD, including persistent airflow limitation and variable airway hyperreactivity.
โ ๏ธ ACOS is associated with worse outcomes than asthma or COPD alone, requiring careful diagnosis and combined treatment strategies.
๐ฌ Pathophysiology
- ๐ช๏ธ Asthma Component: Chronic airway inflammation, eosinophilic infiltration, reversible obstruction (bronchospasm).
- ๐ฅ COPD Component: Irreversible obstruction, neutrophilic inflammation, alveolar destruction (emphysema) or chronic bronchitis.
- โก Overlap Features: Persistent inflammation, airway hyperreactivity, incomplete reversibility of obstruction.
โ ๏ธ Risk Factors
- ๐ฌ Smoking: Major COPD driver; smokers with asthma are at highest risk.
- ๐ต Age: More common in older adults.
- ๐ญ Occupational Exposure: Dust, fumes, chemicals.
- ๐งฌ Genetics: Family history of asthma or COPD.
๐ฉบ Clinical Features
- ๐ฎโ๐จ Dyspnoea: progressive breathlessness, worse on exertion
- ๐คง Chronic cough with sputum (COPD-like)
- ๐ต Wheeze: episodic, asthma-like
- ๐ Frequent exacerbations
- ๐ Nocturnal symptoms (asthma feature)
- ๐ซ Spirometry: persistent airflow limitation, partial reversibility
- Exam: wheeze, hyperinflation, prolonged expiration
๐งช Investigations
- ๐ Spirometry:
- FEV1/FVC < 0.7 (fixed obstruction)
- Partial reversibility: โฅ12% & 200 mL FEV1 improvement, but incomplete normalization
- ๐งช Biomarkers:
- Peripheral eosinophilia โ asthma component
- FeNO โ โ eosinophilic inflammation
- ๐ฉป Imaging:
- Chest X-ray: hyperinflation, bronchial wall thickening
- CT: emphysema, airway changes
๐ Pharmacological Management
- ๐ฟ ICS: reduce inflammation, prevent exacerbations (asthma features)
- ๐จ LABA: bronchodilation (always with ICS)
- ๐ LAMA: target COPD component, reduce exacerbations
- ๐ SABA/SAMA: rescue therapy (e.g., salbutamol, ipratropium)
- โก Oral steroids: only for acute exacerbations
- ๐ LTRA: for allergic/asthmatic overlap
๐โโ๏ธ Non-Pharmacological Management
- ๐ญ Smoking cessation
- ๐๏ธโโ๏ธ Pulmonary rehabilitation: exercise + education
- ๐ Vaccinations: annual influenza + pneumococcal
- ๐ Self-management: inhaler technique, exacerbation recognition
๐จ Exacerbation Management
- ๐จ Short-acting bronchodilators (SABA/SAMA)
- ๐ Systemic steroids: oral prednisolone or IV hydrocortisone
- ๐งซ Antibiotics: if bacterial infection suspected
- ๐ซ Oxygen: if SpOโ < 90%; monitor COโ retention
๐ Prognosis
ACOS has worse outcomes than asthma or COPD alone, including more frequent exacerbations, hospital admissions, and faster lung function decline.
โจ Early recognition, combination therapy (ICS + LABA/LAMA), and lifestyle interventions improve symptom control and quality of life.
๐ NICE References